ArticlePsychosomatic medicine2015
Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study.
Article in Psychosomatic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00078286 (Safety and Efficacy of Sertraline for Depression CHF), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Sertraline for Depression CHF
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis.Molecular psychiatry · 2018Pooled it
- Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD.Kidney360 · 2020Trial
- Use of the PROMIS® Depression scale and the Beck Depression Inventory in patients with heart failure.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2019Trial
- Neurocardiology: Brain-Heart Interactions in the Heart.MedComm · 2026Review
- Assessment the Level of Comorbid Depression, Quality of Life and Associated Factors Among Patients with Heart Failure: An Outpatient-Based Study.Healthcare (Basel, Switzerland) · 2026Article
- The effect of sertraline on depressive symptoms and serum inflammatory factors in adolescent with depression.Psychopharmacology · 2025Article
- Mediators of the Association Between Severity of Noncommunicable Diseases and Subjective Health-Related Quality of Life.Neuropsychopharmacology reports · 2025Article
- Biomarker-based depression risk prediction in chronic heart failure patients: an interpretable machine learning approach.Frontiers in endocrinology · 2025Article
- Exploration of therapeutic models for psycho-cardiology: From cardiac to psychological rehabilitation.Heliyon · 2024Review
- Depression, anxiety, and quality of life as predictors of rehospitalization in patients with chronic heart failure.BMC cardiovascular disorders · 2023Observational
- Neuropsychiatric disorders in patients with heart failure: not to be ignored.Heart failure reviews · 2023Review
- Depression in Heart Failure with Reduced Ejection Fraction, an Undervalued Comorbidity: An Up-To-Date Review.Medicina (Kaunas, Lithuania) · 2023Review
- A bibliometric analysis of research on heart failure comorbid with depression from 2002 to 2021.Heliyon · 2023Review
- Sigma-1 Receptor Signaling: In Search of New Therapeutic Alternatives for Cardiovascular and Renal Diseases.International journal of molecular sciences · 2023Review
- Depressive symptoms, cognitive impairment, and all-cause mortality among REGARDS participants with heart failure.European heart journal open · 2022Article
- The molecular role of Sigmar1 in regulating mitochondrial function through mitochondrial localization in cardiomyocytes.Mitochondrion · 2022Article
- Toll-like receptor 4 methylation grade is linked to depressive symptom severity.Translational psychiatry · 2021Article
- Sigmar1's Molecular, Cellular, and Biological Functions in Regulating Cellular Pathophysiology.Frontiers in physiology · 2021Review
- Interleukin-6 is associated with tryptophan metabolism and signs of depression in individuals with carbohydrate malabsorption.EXCLI journal · 2020Article
- Cardiac Dysfunction in the Sigma 1 Receptor Knockout Mouse Associated With Impaired Mitochondrial Dynamics and Bioenergetics.Journal of the American Heart Association · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundMajor depressive disorder (MDD) and chronic heart failure (CHF) have in common heightening states of inflammation, manifested by elevated inflammation markers such as C-reactive protein. This study compared inflammatory biomarker profiles in patients with CHF and MDD to those without MDD.
methodsThe study recruited patients admitted to inpatient care for acute heart failure exacerbations, after psychiatric diagnostic interview. Patients with Beck Depression Inventory (BDI) scores lower than 10 and with no history of depression served as the nondepressed reference group (n = 25). MDD severity was defined as follows: mild (BDI 10-15; n = 48), moderate (BDI 16-23; n = 51), and severe (BDI ≥ 24; n = 33). A Bio-Plex assay measured 18 inflammation markers. Ordinal logistic models were used to examine the association of MDD severity and biomarker levels.
resultsAdjusting for age, sex, statin use, body mass index, left ventricular ejection fraction, tobacco use, and New York Heart Association class, the MDD overall group variable was significantly associated with elevated interleukin (IL)-2 (p = .019), IL-4 (p = .020), IL-6 (p = .026), interferon-γ (p = .010), monocyte chemoattractant protein 1 (p = .002), macrophage inflammatory protein 1β (p = .003), and tumor necrosis factor α (p = .004). MDD severity subgroups had a greater probability of elevated IL-6, IL-8, interferon-γ, monocyte chemoattractant protein 1, macrophage inflammatory protein 1β, and tumor necrosis factor α compared with nondepressed group. The nondepressed group had greater probability of elevated IL-17 (p < .001) and IL-1β (p < .01).
conclusionsMDD in patients with CHF was associated with altered inflammation marker levels compared with patients with CHF who had no depression. Whether effective depression treatment will normalize the altered inflammation marker levels requires further study.
trial registrationClinicalTrials.gov NCT00078286.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.